Grundlæggende statistik
| LEI | 5493008YRL2KK6TM3819 |
| CIK | 1614744 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Purple Biotech Ltd - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| May 20, 2026 |
Calculation of Filing Fee Tables F-3 PURPLE BIOTECH LTD. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial |
|
| May 20, 2026 |
As filed with the Securities and Exchange Commission on May 20, 2026 As filed with the Securities and Exchange Commission on May 20, 2026 Registration No. |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe |
|
| May 15, 2026 |
Exhibit 99.1 Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights New data from IM1240 (capped-CD3 × 5T4 × NKG2A) tri-specific antibody demonstrated potent anti-tumor activity across all treatment-resistant patient-derived tumor samples Established CAPTN-3 Scientific Advisory Board with leading experts in T-cell engager development, NK cell biology and translational |
|
| April 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 27, 2026 |
Exhibit 99.1 Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240 Data, generated in the lab of Dr. Amir Horowitz of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, demonstrated that all tested patient-derived tumor samples (n=7) responded to IM1240 treatment New data shows that the NKG2A arm significantly enhanced anti-tumor activity in all sample |
|
| April 23, 2026 |
Exhibit 99.1 Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement toward clinical-stage immunotherapy development SAB leverages expertise in translational science, NK and T cell biology REHOVOT, |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 25, 2026 |
Exhibit 99.1 Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform Collaboration leverages Converge Bio’s proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule q |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 19, 2026 |
Exhibit 99.1 CORPORATE PRESENTATION March 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act o |
|
| March 19, 2026 |
CERTIFICATION OF CHIEF FINACIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION OF CHIEF FINACIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2025, t |
|
| March 19, 2026 |
Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of our share capital and certain provisions of our articles of association are summaries and do not purport to be complete. The description is qualified by reference to our corporate documents, copies of which are filed with the SEC as exhibits to the Annual Report on Form 20-F of which this Exhibit forms a part. Authorized Share C |
|
| March 19, 2026 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2025, |
|
| March 19, 2026 |
Exhibit 1.2 The Companies Law, 5759-1999 A Company Limited By Shares Amended and Restated Articles of Association of Purple Biotech Ltd. Israeli Public Company Number 520031238 Interpretation; General 1. In these Articles of Association (“Articles”), unless the context otherwise prescribes, the meaning of the following words shall be as follows: “person” - includes a corporate body (unless otherwi |
|
| March 19, 2026 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Shai Lankry, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 19, 2026 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No. 333-270769 on Form F-3, and registration statements No. 333-211478, No. 333-218538, No. 333-230584, No. 333-238481 and No. 333-264107 on Form S-8 of our re |
|
| March 19, 2026 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ |
|
| March 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 17, 2026 |
Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 Purple Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement REHOVOT, Israel, March 17, 2026 – Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced that it received confirmation from the |
|
| March 17, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 13, 2026 |
Exhibit 99.2 Purple Biotech Announces CEO Transition Gil Efron to Step Down as CEO in August 2026 for Health Considerations; Will Continue to Lead Corporate Development REHOVOT, Israel, March 13, 2026 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company developing next-generation cancer therapies, today announced that Gil Efron, Chief Executive Officer, will step do |
|
| March 13, 2026 |
Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results Prioritized development of first tri-specific antibody from the CAPTN-3 platform, IM1240, targeting 5T4 tumor-associated antigen, and second tri-specific antibody, IM1305, named as development candidate, targeting TROP2 Achieved toxicology and manufacturing milestones for IM1240, demonstrating an expanded thera |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| February 25, 2026 |
Exhibit 99.1 Purple Biotech Announces Plan to Implement ADS Ratio Change ADS Will Begin Trading Reflecting the Ratio Change on March 2, 2026 REHOVOT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizi |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| January 13, 2026 |
Exhibit 99.1 CORPORATE PRESENTATION January 2026 Advancing the next Generation of Immuno - oncology NASDAQ/TASE : PPBT Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements in |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2026 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| January 7, 2026 |
Exhibit 99.1 Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240 IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator IM1240’s pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human s |
|
| December 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 11, 2025 |
Exhibit 99.1 Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025 Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptom |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| November 19, 2025 |
Exhibit 99.1 NASDAQ/TASE: PPBT November 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements includ |
|
| November 14, 2025 |
Exhibit 99.1 Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the fir |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 29, 2025 |
Exhibit 99.1 Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, adv |
|
| October 28, 2025 |
Exhibit 99.2 PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved Purple Biotech Ltd. Extraordinary General Meeting of Shareholders For Shareholders of record as of November 3 , 2025 Monday, December 15 , 2025 4 : 30 PM, Israel Time 4 Oppenheimer Street, Science Park, Rehovot, Israel YOUR VOTE IS IMPORTAN |
|
| October 28, 2025 |
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Monday, December 15, 2025, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel. The purpose of the Meeting is to approve |
|
| October 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 20, 2025 |
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification REHOVOT, Israel, October 20, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that on October 16, 2025, it received a le |
|
| September 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File No.: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| September 19, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT September 19, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Purple Biotech Ltd., a corporation organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when |
|
| September 19, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To Prospectus dated May 22, 2023) Up to $2,300,000 American Depositary Shares each representing two hundred (200) Ordinary Shares Purple Biotech Ltd. We have entered into an At The Market Offering Agreement, dated September 19, 2025 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC (“Wainwright”) relating to |
|
| September 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 16, 2025 |
Exhibit 99.1 NASDAQ/TASE: PPBT September 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inclu |
|
| September 10, 2025 |
Exhibit 99.1 Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Compa |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 5, 2025 |
Exhibit 99.1 Purple Biotech Announces Pricing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-c |
|
| September 5, 2025 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Exhibit 4.2 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, |
|
| September 5, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 4, 2025 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHER |
|
| September 5, 2025 |
Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “ |
|
| September 5, 2025 |
Exhibit 4.3 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: September 5, 2025 Issue Date: September 5, 2025 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assi |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 5, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-289927 PROSPECTUS 3,055,000 American Depositary Shares representing 611,000,000 Ordinary Shares 2,944,999 Pre-Funded Warrants to Purchase up to 588,999,800 American Depositary Shares 11,999,998 Series B Warrants to Purchase up to 2,399,999,600 American Depositary Shares 420,000 Placement Agent Warrants to Purchase up to 84,000,000 American Depo |
|
| September 4, 2025 |
Exhibit 99.1 Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and th |
|
| September 4, 2025 |
X0101 EFFECT 33 LIVE 2025-09-04 09:00:00 F-1 0001614744 PURPLE BIOTECH LTD. 333-289927 |
|
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 3, 2025 |
Exhibit 99.1 Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2 Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with Investigational New Drug (IND) submissi |
|
| August 29, 2025 |
430 Park Avenue | New York, New York 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC Exhibit 1.2 Execution Version August 4, 2025 STRICTLY CONFIDENTIAL Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Attn: Gil Efron, Chief Executive Officer Dear Mr. Efron: This letter agreement (this “Agreement”) constitutes the agreement between Purple Biotech Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclu |
|
| August 29, 2025 |
Exhibit 4.14 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, |
|
| August 29, 2025 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Exhibit 4.15 WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and su |
|
| August 29, 2025 |
430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com Member: FINRA/SIPC August 29, 2025 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Purple Biotech Ltd. Registration Statement on Form F-1 (Registration No. 333-289927) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursu |
|
| August 29, 2025 |
Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel August 29, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Lauren Hamill Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed August 29, 2025 File No. 333-289927 (the “Registration Stat |
|
| August 29, 2025 |
Exhibit 10.24 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| August 29, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-1 PURPLE BIOTECH LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary shares, |
|
| August 29, 2025 |
As filed with the Securities and Exchange Commission on August 29, 2025 As filed with the Securities and Exchange Commission on August 29, 2025 Registration No. |
|
| August 29, 2025 |
Exhibit 4.16 PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: , 2025 Issue Date: , 2025 THIS PLACEMENT AGENT WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| August 6, 2025 |
Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2025 Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025 Contents Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025 1 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed Consolidated Unaudi |
|
| August 6, 2025 |
Exhibit 99.1 Purple Biotech Reports Second Quarter 2025 Financial Results Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 23, 2025 |
Exhibit 99.1 Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, |
|
| July 15, 2025 |
July 15, 2025 Gil Efron Chief Executive Officer Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Re: Purple Biotech Ltd. Draft Registration Statement on Form F-1 Submitted July 10, 2025 CIK No. 0001614744 Dear Gil Efron: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at le |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 10, 2025 |
As confidentially submitted to the Securities and Exchange Commission on July 10, 2025. |
|
| July 10, 2025 |
Exhibit 99.1 NASDAQ/TASE: PPBT July 2025 CORPORATE PRESENTATION 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements include, b |
|
| June 23, 2025 |
Exhibit 99.1 Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, t |
|
| June 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 17, 2025 |
Exhibit 99.1 Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Pur |
|
| June 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| May 21, 2025 |
Exhibit 99.1 Purple Biotech Reports First Quarter 2025 Financial Results Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 dif |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe |
|
| May 12, 2025 |
6-K 1 ea0241701-6kpurplebio.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street |
|
| May 12, 2025 |
Exhibit 99.1 Purple Biotech Appoints Shai Lankry as Chief Financial Officer U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purpl |
|
| May 6, 2025 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT May 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inclu |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe |
|
| April 30, 2025 |
Exhibit 99.1 Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups ● Statistically significant efficacy in biomarker subgroup analyses was observed: o 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ran |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 28, 2025 |
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers Exhibit 99.1 Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers ● Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancer ● NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benef |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 16, 2025 |
Exhibit 99.1 Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in colorectal canc |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 1, 2025 |
Exhibit 99.1 Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025 REHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announ |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 28, 2025 |
Exhibit 99.1 Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today an |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 18, 2025 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT March 2025 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inc |
|
| March 10, 2025 |
Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the st |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Add |
|
| March 10, 2025 |
Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL The following description of our share capital and certain provisions of our articles of association are summaries and do not purport to be complete. The description is qualified by reference to our corporate documents, copies of which are filed with the SEC as exhibits to the Annual Report on Form 20-F of which this Exhibit forms a part. Authorized Share C |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 10, 2025 |
Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINACIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 10, 2025 |
Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase NT219 headed into P |
|
| March 10, 2025 |
Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results Completed successful clinical trials for CM24 and NT219 oncology assets, demonstrating clinical benefits and identifying potential biomarkers CM24 is well positioned for personalized treatment, with planned biomarker-driven Phase 2b study based on serum biomarkers CEACAM1 and myeloperoxidase NT219 headed into P |
|
| March 10, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No. 333-270769 on Form F-3, registration statements No. 333-235729, No. 333-275216 and No. 333-280947 on Form F-1, and registration statements No. 333-211478, |
|
| March 10, 2025 |
PURPLE BIOTECH LTD. (the “Company”) INSIDER TRADING POLICY Dated: March [●], 2025 Exhibit 4.23 PURPLE BIOTECH LTD. (the “Company”) INSIDER TRADING POLICY Dated: March [●], 2025 As a dual-listed company whose securities are publicly traded on the Tel Aviv Stock Exchange ("TASE") and on the NASDAQ Stock Market ("NASDAQ"), the Company is subject to various rules and regulations, including, the Israeli Companies Law, 5759-1999 (the "Companies Law"), the Israeli Securities Law, 5728 |
|
| March 5, 2025 |
6-K 1 ea0233219-6kpurple.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, |
|
| March 5, 2025 |
Exhibit 99.1 Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and neck cancer REHOVOT, Israel, March 05, 2025 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPB |
|
| February 28, 2025 |
Exhibit 99.2 |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 28, 2025 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Tuesday, April 15, 2025, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel, for the following purposes: 1. To re-elect each of Dr. E |
|
| February 18, 2025 |
Exhibit 99.1 Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The study is conducted in collaboration with the University of Colorado Anschutz Medical Campus and is led |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 3, 2025 |
Exhibit 99.1 Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform ● Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types. ● CAPTN-3 antibodies are designed to promote in |
|
| January 6, 2025 |
Purple Biotech Ltd. Up to $1,330,000 American Depositary Shares Representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023) Purple Biotech Ltd. Up to $1,330,000 American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 22, 2023, filed with the Secu |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2025 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| December 6, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT December 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 5, 2024 |
Exhibit 99.1 Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares REHOVOT, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced the closing of its pr |
|
| December 4, 2024 |
Exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 3, 2024 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREA |
|
| December 4, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 4, 2024 |
472,668 American Depositary Shares representing 94,533,600 Ordinary Shares Purple Biotech Ltd. Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To prospectus dated May 22, 2023) 472,668 American Depositary Shares representing 94,533,600 Ordinary Shares Purple Biotech Ltd. We are offering 472,668 American Depositary Shares (“ADSs”) in this offering to institutional investors pursuant to this prospectus supplement and accompanying prospectus and a securities |
|
| December 3, 2024 |
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares Exhibit 99.1 Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares REHOVOT, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced that it has entered into a defin |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 2, 2024 |
Exhibit 99.1 Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer · Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement across all efficacy endpoints · A biomarker enriched patient population analysis based on pretreatment ranges of serum CEACAM1 demonstrated signi |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| November 15, 2024 |
Exhibit 99.1 Purple Biotech Reports Third Quarter 2024 Financial Results Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identified and associated with CM24 novel targets CAPTN-3 tri-specific antibody platform data presented at the ENA Symposium October 2 |
|
| November 14, 2024 |
IL:PPBT / Purple Biotech Ltd / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-ppbt093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* PURPLE BIOTECH LTD. (Name of Issuer) American Depositary Shares, each representing 10 Ordinary Shares (Title of Class of Securities) 74638P208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of |
|
| November 4, 2024 |
Exhibit 99.1 Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24 Definition of serum biomarkers for patient selection offers |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 25, 2024 |
EX-99.1 2 ea021864301ex99-1purple.htm PRESS RELEASE ISSUED BY PURPLE BIOTECH LTD. ON OCTOBER 25, 2024 Exhibit 99.1 Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 demonstrates sustained tumor regression in a triple negative breast cancer in-vivo m |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 10, 2024 |
Exhibit 99.1 Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAPTN-3 is a conditionally activated tri-specific antibody platform that features novel dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response against cancer REHOVOT, Israel, Oct. 10, 2024 (GLOBE NE |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 9, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT October 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements i |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| September 18, 2024 |
Exhibit 99.1 Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 ● High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients (HR=0.1 and prolongation of 4.1 mo |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of September 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of princip |
|
| August 19, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT August 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements in |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| August 16, 2024 |
Exhibit 99.2 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements As of June 30, 2024 Purple Biotech Ltd. Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2024 Contents Page Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2024 Condensed Consolidated Unaudited Interim Statements of Financial Position 2 Condensed C |
|
| August 16, 2024 |
Exhibit 99.1 Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, progression free survival, objective response rate and all other efficacy endpoints in the combination o |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of August 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| July 31, 2024 |
11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares Purple Biotech Ltd. Filed Pursuant to Rule 424(b)(3) Registration No. 333-280947 PROSPECTUS 11,661,364 American Depositary Shares representing 116,613,640 Ordinary Shares Purple Biotech Ltd. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 11,661,364 American Depositary Shares (the “Offered ADSs”), with each American Depositary Share |
|
| July 26, 2024 |
Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel July 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed July 22, 2024 File No. 333-280947 (the “Registration Statemen |
|
| July 26, 2024 |
July 26, 2024 Lior Fhima Chief Financial Officer Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed July 22, 2024 File No. 333-280947 Dear Lior Fhima: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acc |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 25, 2024 |
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule Exhibit 99.1 Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today announced that on July 24, 2024, |
|
| July 22, 2024 |
As filed with the Securities and Exchange Commission on July 22, 2024 As filed with the Securities and Exchange Commission on July 22, 2024 Registration No. |
|
| July 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd. |
|
| July 19, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT July 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements incl |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 2, 2024 |
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds Exhibit 99.1 Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds REHOVOT, Israel, July 2, 2024 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced exercise o |
|
| July 2, 2024 |
Exhibit 1.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 2, 2024 |
Exhibit 1.2 Purple Biotech Ltd. July 1, 2024 Holder of Existing Warrants Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs Dear Holder: Purple Biotech Ltd. (the “Company”) is pleased to offer to you (“Holder,” “you” or similar terminology) the opportunity to receive (i) new warrants to purchase American Depositary Shares (“ADSs”), each representing |
|
| July 2, 2024 |
Exhibit 1.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 2, 2024 |
Exhibit 1.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-235327 PROSPECTUS SUPPLEMENT (To Prospectus Supplements Dated October 19, 2023 and June 23, 2020, to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,900 Ordinary Shares Warrants to Purchase up to 1,944,445 American Depositary Shares Placement Agent Warrants to Purchase up to 194,445 American Deposita |
|
| July 2, 2024 |
Exhibit 1.1 Purple Biotech Ltd. July 1, 2024 Holder of Existing Warrants Re: Inducement Offer to Exercise Existing Warrants to Purchase Ordinary Shares Represented by ADSs Dear Holder: Purple Biotech Ltd. (the “Company”) is pleased to offer to you (“Holder,” “you” or similar terminology) the opportunity to receive (i) new warrants to purchase American Depositary Shares (“ADSs”), each representing |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of July 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| July 1, 2024 |
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds Exhibit 99.1 Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreeme |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 27, 2024 |
Exhibit 99.1 Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit ● New data suggests that baseline serum myeloperoxidase (MPO) levels below the threshold may predict overall survival (OS) improvement when comparing the CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IR |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 26, 2024 |
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is hereby given that an Annual General Meeting of Shareholders (the “Meeting”) of Purple Biotech Ltd. (the “Company”) will be held on Thursday, August 8, 2024, at 4:30 p.m. Israel time at the Company’s executive offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel. The purpose of the Meeting is to approve the re-electio |
|
| June 26, 2024 |
Exhibit 99.2 |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 4, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT June 2024 CORPORATE PRESENTATION Forward - looking Statements and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements incl |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of June 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal ex |
|
| June 3, 2024 |
Exhibit 99.1 Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer ● 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe |
|
| May 21, 2024 |
Exhibit 99.1 Purple Biotech Reports First Quarter 2024 Financial Results CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024 REHOVOT, Israel, May 21, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal exe |
|
| May 2, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT May 2024 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements inclu |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| April 25, 2024 |
Exhibit 99.1 Purple Biotech’s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company |
|
| March 28, 2024 |
Exhibit 99.1 Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech" |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 14, 2024 |
Exhibit 99.1 Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 6, 2024 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT March 2024 CORPOR A TE PRESEN T A TION Fo r war d - lo o kin g Sta t em e nt s and Safe Harbor | 2 Certain statements in this presentation that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - lookin |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 5, 2024 |
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.1 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Gil Efron, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of March 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal e |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O |
|
| March 5, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2023, |
|
| March 5, 2024 |
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results Exhibit 99.1 Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results REHOVOT, Israel, March 5, 2024 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results |
|
| March 5, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in registration statements No. 333-226195, No. 333-233793, No. 333-233795, No. 333-238229, No. 333-239807, No. 333-268710 and No. 333-270769 on Form F-3, registration statements, No. 333-235729 and 333-275216 on Form F-1, and registration statements No. 333-211478, No. 333-218538, No. |
|
| March 5, 2024 |
CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 13.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Purple Biotech Ltd. (the “Company”) hereby certifies, to such officer’s knowledge that: 1. The Company’s Annual Report on Form 20-F for the year ended December 31, 2023, |
|
| March 5, 2024 |
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 12.2 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Lior Fhima, certify that: 1. I have reviewed this annual report on Form 20-F of Purple Biotech Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 27, 2024 |
Exhibit 99.1 Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Comp |
|
| February 14, 2024 |
SC 13G 1 armistice-ppbt123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PURPLE BIOTECH LTD. (Name of Issuer) American Depositary Shares, each representing 10 Ordinary Shares (Title of Class of Securities) 74638P109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this St |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 13, 2024 |
Exhibit 99.1 Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the pow |
|
| February 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of February 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| February 1, 2024 |
Purple Biotech Reaches Recommended Phase 2 Dose for NT219 Exhibit 99.1 Purple Biotech Reaches Recommended Phase 2 Dose for NT219 REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of January 2024 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| December 20, 2023 |
Exhibit 99.1 Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASD |
|
| December 14, 2023 |
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial Exhibit 99.1 Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the |
|
| December 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of December 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| November 21, 2023 |
Purple Biotech Reports Third Quarter 2023 Financial Results Exhibit 99.1 Purple Biotech Reports Third Quarter 2023 Financial Results Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash Runway Extended to 2H 2025 through Recent Financing REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple B |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| November 21, 2023 |
| 1 NASDAQ/TASE: PPBT November 2023 CORPO R A TE PRESEN T A TION Exhibit 99.1 | 1 NASDAQ/TASE: PPBT November 2023 CORPO R A TE PRESEN T A TION Fo r ward - lookin g Sta t emen t s and Saf e Harbor | 2 Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - look |
|
| November 14, 2023 |
4,652,175 American Depositary Shares representing 46,521,750 Ordinary Shares Purple Biotech Ltd. Filed Pursuant to Rule 424(b)(3) Registration No. 333-275216 PROSPECTUS 4,652,175 American Depositary Shares representing 46,521,750 Ordinary Shares Purple Biotech Ltd. This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 4,652,175 American Depositary Shares (the “Offered ADSs”), with each American Depositary Share (“ |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel Purple Biotech Ltd. 4 Oppenheimer Street, Science Park Rehovot 7670104, Israel November 13, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street N.E. Washington, D.C. 20549 Attention: Jason Drory Re: Purple Biotech Ltd. Registration Statement on Form F-1 Filed October 30, 2023 File No. 333-275216 (the “Registration Sta |
|
| November 2, 2023 |
Exhibit 99.1 Purple Biotech Fortifies NT219 Patent Protection New patent granted in China for pharmaceutical composition of NT219 expands IP protection REHOVOT, Israel, Nov. 02, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to over |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of November 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principa |
|
| October 30, 2023 |
As filed with the Securities and Exchange Commission on October 30, 2023 As filed with the Securities and Exchange Commission on October 30, 2023 Registration No. |
|
| October 30, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Purple Biotech Ltd. |
|
| October 19, 2023 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 19, 2023 |
exhibit 4.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 17, 2023 by and between Purple Biotech Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREA |
|
| October 19, 2023 |
Purple Biotech Announces Closing of $5 Million Registered Direct Offering Exhibit 99.1 Purple Biotech Announces Closing of $5 Million Registered Direct Offering REHOVOT, Israel, October 19, 2023 - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced the closing of i |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 19, 2023 |
Exhibit 4.4 October 17, 2023 Holder of Warrants to Purchase Ordinary Shares represented by ADSs issued on June 23, 2020 and June 1, 2018 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the registered offering on or about the date hereof (the “Offering”) by Purple Biotech Ltd. (the “Company”) of its ordinary shares, no par value (the “Ordinary Shares”), represented by it |
|
| October 19, 2023 |
Exhibit 4.2 PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Number of American Depositary Shares: [] Initial Exercise Date: [], 2023 Issue Date: [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitl |
|
| October 19, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-235327 PROSPECTUS SUPPLEMENT (To Prospectus Supplement Dated June 23, 2020 to Prospectus dated December 13, 2019) 3,888,890 American Depositary Shares Representing 38,888,892 Ordinary Shares Warrants to Purchase up to 1,944,445 American Depositary Shares Placement Agent Warrants to Purchase up to 194,445 American Depositary Shares American Depo |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 19, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (To prospectus dated May 22, 2023) 2,430,000 American Depositary Shares representing 24,300,000 Ordinary Shares Pre-funded Warrants to Purchase up to 1,917,827 American Depositary Shares Up to 1,917,827 American Depositary Shares representing 19,178,270 Ordinary Shares underlying the Pre-funded Warrants Purple Biote |
|
| October 19, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES PURPLE BIOTECH LTD. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
|
| October 17, 2023 |
Purple Biotech Ltd. Up to USD 3,000,000 American Depositary Shares Representing Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-268710 PROSPECTUS SUPPLEMENT (to Prospectus dated May 22, 2023) Purple Biotech Ltd. Up to USD 3,000,000 American Depositary Shares Representing Ordinary Shares This prospectus supplement amends and supplements the information in the sales agreement prospectus, dated May 22, 2023, filed with the Securities and Exchange Commission as a part of ou |
|
| October 17, 2023 |
Purple Biotech Announces $5 Million Registered Direct Offering Exhibit 99.1 Purple Biotech Announces $5 Million Registered Direct Offering REHOVOT, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) - Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced that it has e |
|
| October 13, 2023 |
Exhibit 99.1 | 1 NASDAQ/TASE: PPBT October 2023 CORPORATE PRESENTATION | 2 Forward - looking Statements and Safe Harbor Certain statements in this press release that are forward - looking and not statements of historical fact are forward - looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Such forward - looking statements |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of October 2023 Commission File Number: 001-37643 PURPLE BIOTECH LTD. (Translation of registrant’s name into English) 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (Address of principal |
